Research programme: metabotropic glutamate receptor modulators - Merz Pharmaceuticals GmbH

Drug Profile

Research programme: metabotropic glutamate receptor modulators - Merz Pharmaceuticals GmbH

Alternative Names: (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate; [(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; A-841720; EMQMCM; MTEP

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merz Pharmaceuticals GmbH
  • Class
  • Mechanism of Action Metabotropic glutamate receptor antagonists; Metabotropic glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Cognition disorders; Drug-induced dyskinesia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in Germany (Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in Germany (Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in Germany (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top